Source: Snaxshot by Andrea Hernández
The essay links food-industry cost-cutting—optimizing for shareholder returns over nutrition—to surging GLP-1 adoption as a consumer workaround. Rather than treating weight-loss drugs as a wellness trend, it frames them as a market correction: when grocers stop competing on food quality and consumers distrust shelf products, pharmaceutical intervention becomes the easier choice. This points to a structural split: one economy for people who can afford to exit industrial food systems, another for those who medicate around them.